This article was originally published in The Gray Sheet
Introducing in the U.S. the Alcyon 300 and 300i bench-top clinical chemistry analyzers for routine and special chemistry testing at labs running fewer than 1,000 tests per day or 100,000 tests annually. Both analyzers received 510(k) clearance in February and offer a "49-assay menu of liquid reagents, an automated cuvette handler, 39 sample holders, 24 reagent positions and the ability to process up to 300 photometric tests per hour," the firm says. The initial menu of assays is expected to increase to 60 "within a year," while another 30 assays are under development, Abbott notes. The 300i offers an integrated ISE (chloride, potassium, sodium) module. The systems are based on technology developed by French manufacturer Alcyon Analyzer, which Abbott acquired in 1997 ("The Gray Sheet" Feb. 10, In Brief)
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.